DE69736244D1 - Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten - Google Patents

Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten

Info

Publication number: DE69736244D1
Authority: DE; Germany
Prior art keywords: lymphotoxin; antibodies; lymphotoxine; treatment; immunological diseases
Prior art date: 1996-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69736244T

Other languages

English (en)

Other versions

DE69736244T2 (de

Inventor

Jeffrey Browning

Susan Hochman

D Rennert

Fabienne Mackay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biogen Inc

Biogen MA Inc

Original Assignee

Biogen Idec Inc

Biogen Idec MA Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-25

Filing date

1997-10-24

Publication date

2006-08-10

1997-10-24 Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc

2006-08-10 Publication of DE69736244D1 publication Critical patent/DE69736244D1/de

2007-05-31 Application granted granted Critical

2007-05-31 Publication of DE69736244T2 publication Critical patent/DE69736244T2/de

2017-10-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
AIDS & HIV (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE69736244T 1996-10-25 1997-10-24 Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten Expired - Lifetime DE69736244T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2906096P	1996-10-25	1996-10-25
US29060P		1996-10-25
PCT/US1997/019436 WO1998017313A2 (en)	1996-10-25	1997-10-24	Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Publications (2)

Publication Number	Publication Date
DE69736244D1 true DE69736244D1 (de)	2006-08-10
DE69736244T2 DE69736244T2 (de)	2007-05-31

Family

ID=21847003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69736244T Expired - Lifetime DE69736244T2 (de)	1996-10-25	1997-10-24	Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten

Country Status (26)

Country	Link
EP (1)	EP0954333B1 (de)
JP (1)	JP4299887B2 (de)
KR (1)	KR100584704B1 (de)
CN (2)	CN100382844C (de)
AT (1)	ATE331531T1 (de)
AU (1)	AU726357B2 (de)
BG (1)	BG63565B1 (de)
BR (1)	BR9712670A (de)
CA (1)	CA2269614A1 (de)
CZ (1)	CZ142899A3 (de)
DE (1)	DE69736244T2 (de)
DK (1)	DK0954333T3 (de)
EA (1)	EA002983B1 (de)
EE (1)	EE05213B1 (de)
ES (1)	ES2268727T3 (de)
HK (1)	HK1025500A1 (de)
HU (1)	HU226467B1 (de)
IL (1)	IL129527A (de)
IS (1)	IS5031A (de)
NO (1)	NO328540B1 (de)
NZ (1)	NZ335353A (de)
PL (1)	PL190617B1 (de)
PT (1)	PT954333E (de)
SK (1)	SK55399A3 (de)
TR (1)	TR199901636T2 (de)
WO (1)	WO1998017313A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925351A (en)	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en)	1997-07-07	2006-10-10	La Jolla Institute For Allergy And Immunology	Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) *	1997-07-07	2000-10-31	La Jolla Institute For Allergy And Immunology	Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en)	1997-07-07	2006-02-14	La Jolla Institute For Allergy And Immunology	Antibodies to p30 polypeptides and methods making and using same
EP1119370B1 (de) *	1998-10-09	2006-06-14	Biogen Idec MA Inc.	Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) *	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
JP3822822B2 (ja) *	1999-06-28	2006-09-20	ビーエーエスエフアクチェンゲゼルシャフト	腫瘍の成長を予防する方法
DE19939653A1 (de) *	1999-08-13	2001-02-22	Thomas Huenig	Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) *	2000-03-13	2001-10-25	La Jolla Institute For Allergy And Immunology	Ligand for herpes simplex virus entry mediator and methods of use
EP1674575B1 (de) *	2000-04-12	2010-10-06	La Jolla Institute For Allergy And Immunology	Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
AU2003303339A1 (en) *	2002-12-20	2004-07-22	Biogen Idec Ma Inc.	Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
PE20080980A1 (es)	2006-10-12	2008-09-02	Genentech Inc	Anticuerpos anti-linfotoxina alfa
SG178002A1 (en)	2006-10-20	2012-02-28	Biogen Idec Inc	Treatment of demyelinating disorders
US8338376B2 (en)	2006-10-20	2012-12-25	Biogen Idec Ma Inc.	Compositions comprising variant LT-B-R-IG fusion proteins
US20120070436A1 (en) *	2009-05-28	2012-03-22	Richard Lewis Easeman	Antigen-binding proteins
EP3807401A1 (de) *	2018-06-15	2021-04-21	Universität Bern	Liganden gegen light oder dessen rezeptor ltssr zur verwendung bei hämatologischen malignomen
KR102360196B1 (ko)	2019-10-30	2022-02-08	주식회사 친환경테크	다용도 시트 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69334224D1 (de) *	1992-12-04	2008-07-17	Biogen Idec Inc	Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

1997
- 1997-10-24 EA EA199900409A patent/EA002983B1/ru not_active IP Right Cessation
- 1997-10-24 DK DK97913798T patent/DK0954333T3/da active
- 1997-10-24 ES ES97913798T patent/ES2268727T3/es not_active Expired - Lifetime
- 1997-10-24 CN CNB971999066A patent/CN100382844C/zh not_active Expired - Fee Related
- 1997-10-24 CZ CZ991428A patent/CZ142899A3/cs unknown
- 1997-10-24 DE DE69736244T patent/DE69736244T2/de not_active Expired - Lifetime
- 1997-10-24 KR KR1019997003619A patent/KR100584704B1/ko not_active IP Right Cessation
- 1997-10-24 JP JP51968898A patent/JP4299887B2/ja not_active Expired - Fee Related
- 1997-10-24 PL PL97332972A patent/PL190617B1/pl not_active IP Right Cessation
- 1997-10-24 CA CA002269614A patent/CA2269614A1/en not_active Abandoned
- 1997-10-24 SK SK553-99A patent/SK55399A3/sk unknown
- 1997-10-24 IL IL129527A patent/IL129527A/en not_active IP Right Cessation
- 1997-10-24 BR BR9712670-5A patent/BR9712670A/pt not_active Application Discontinuation
- 1997-10-24 AU AU50896/98A patent/AU726357B2/en not_active Ceased
- 1997-10-24 WO PCT/US1997/019436 patent/WO1998017313A2/en active IP Right Grant
- 1997-10-24 EP EP97913798A patent/EP0954333B1/de not_active Expired - Lifetime
- 1997-10-24 AT AT97913798T patent/ATE331531T1/de active
- 1997-10-24 CN CNA200810082273XA patent/CN101239186A/zh active Pending
- 1997-10-24 TR TR1999/01636T patent/TR199901636T2/xx unknown
- 1997-10-24 EE EEP199900146A patent/EE05213B1/xx not_active IP Right Cessation
- 1997-10-24 HU HU9904516A patent/HU226467B1/hu not_active IP Right Cessation
- 1997-10-24 NZ NZ335353A patent/NZ335353A/xx not_active IP Right Cessation
- 1997-10-24 PT PT97913798T patent/PT954333E/pt unknown
1999
- 1999-04-21 IS IS5031A patent/IS5031A/is unknown
- 1999-04-22 NO NO19991926A patent/NO328540B1/no not_active IP Right Cessation
- 1999-05-20 BG BG103416A patent/BG63565B1/bg unknown
2000
- 2000-04-10 HK HK00101942A patent/HK1025500A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO991926D0 (no)	1999-04-22
NO991926L (no)	1999-06-25
CN1237910A (zh)	1999-12-08
ATE331531T1 (de)	2006-07-15
JP4299887B2 (ja)	2009-07-22
EE05213B1 (et)	2009-10-15
IL129527A0 (en)	2000-02-29
BG103416A (en)	2000-01-31
NO328540B1 (no)	2010-03-15
BG63565B1 (bg)	2002-05-31
NZ335353A (en)	2000-09-29
EP0954333A2 (de)	1999-11-10
BR9712670A (pt)	1999-10-19
HU226467B1 (en)	2008-12-29
KR100584704B1 (ko)	2006-05-30
IL129527A (en)	2006-12-10
PL190617B1 (pl)	2005-12-30
TR199901636T2 (xx)	1999-09-21
CA2269614A1 (en)	1998-04-30
PT954333E (pt)	2006-10-31
KR20000052800A (ko)	2000-08-25
IS5031A (is)	1999-04-21
WO1998017313A3 (en)	1998-07-30
EP0954333B1 (de)	2006-06-28
EA199900409A1 (ru)	2000-02-28
SK55399A3 (en)	2000-10-09
AU5089698A (en)	1998-05-15
HUP9904516A3 (en)	2002-09-30
HUP9904516A2 (hu)	2000-05-28
EA002983B1 (ru)	2002-12-26
AU726357B2 (en)	2000-11-02
WO1998017313A2 (en)	1998-04-30
HK1025500A1 (en)	2000-11-17
EE9900146A (et)	1999-12-15
ES2268727T3 (es)	2007-03-16
JP2001502697A (ja)	2001-02-27
CN101239186A (zh)	2008-08-13
PL332972A1 (en)	1999-10-25
CZ142899A3 (cs)	1999-07-14
DE69736244T2 (de)	2007-05-31
DK0954333T3 (da)	2006-10-23
CN100382844C (zh)	2008-04-23

Publication	Publication Date	Title
DE69736244D1 (de)	2006-08-10	Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
DE69633624D1 (de)	2004-11-18	Lösliche lymphotoxin-beta -rezeptoren, antikörper gegen den lymphotoxinrezeptor und ligand-antikörper als therapeutische reagenzien in der behandlung von immunkrankheiten
DK1157042T3 (da)	2008-12-08	Fremstilling af tetravalente antistoffer
DK0741784T3 (da)	2009-06-22	Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
NO982062L (no)	1998-07-06	Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EA200100822A1 (ru)	2002-02-28	Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
ATE390917T1 (de)	2008-04-15	Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
TR199900318T2 (xx)	1999-05-21	IL-8 resept�r antagonistleri.
GR3025698T3 (en)	1998-03-31	NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
DK1021534T3 (da)	2010-02-01	Hepatitis C-receptorprotein CD81
DE60020970D1 (de)	2005-07-28	Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
EP1723967A3 (de)	2007-01-10	Lösliche Lymphotoxin-beta Rezeptoren, Antikörper gegen Lymphotoxin und Antikörper gegen Lymphotoxinligand als therapeutische Agenzien zur Behandlung immunogischer Krankheiten

Legal Events

Date	Code	Title	Description
2007-07-19	8364	No opposition during term of opposition